PGx, the study of how genes affect a person’s response to drugs, combines the fields of pharmacology and genomics to develop effective, safe medications and dosing recommendations tailored to a person’s genetic makeup. PGx testing may help reduce adverse drug reactions (ADRs), which some estimates place as the fourth leading cause of death – resulting in more deaths than lung disease, diabetes, AIDS, pneumonia, and accidents. For every healthcare dollar spent on medications, an additional 50% is spent on addressing ADRs. Admera Health’s flagship product, PGxOne™ Plus, is a comprehensive test built on the foundation of enabling smarter and safer medication management. The test incorporates next-generation gene sequencing design applications and expert data curation to deliver biological systems based medically actionable results. In addition to PGx services, Admera Health leverages existing knowledge and infrastructure to offer related clinical services and robust biopharmaceutical genomics solutions to researchers worldwide.
Location: United States, New Jersey, South Plainfield
Employees: 51-200
Phone: +1 908-222-0533
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | Westfield ... | westfieldb... |
Mentions in press and media 16
| Date | Title | Description |
| 02.09.2025 | Old Dominion University and Admera Health Partner to Advance Alzheimer's Research with Innovative AI Platform | Welcome to the Advanced Molecular Era ODU & Admera Health collaborate on a grant-funded project to build a generative AI platform linking genes to Alzheimer's progression & cognitive decline. SOUTH PLAINFIELD, NJ, UNITED STATES, Sep... |
| 21.08.2025 | BioEcho Unveils EchoLUTION™ Cell Culture RNA Kit, Delivering Superior Quality and Speed for Research | BioEcho EchoLUTION Cell Culture RNA Kit BioEcho An Admera Company BioEcho launches new EchoLUTION™ Cell Culture RNA kit, offering superior quality and speed for academic and biopharma research in under 10 minutes. COLOGNE, GERMANY, August 2... |
| 05.08.2025 | Admera Health Earns CAP Re-Accreditation, Solidifying Position as a Leader in Next-Generation Sequencing and Biopharma | Admera Health The Team At Admera Health Admera Health's CAP re-accreditation highlights a decade of leadership and commitment to top-quality sequencing and biopharma solutions worldwide. SOUTH PLAINFIELD, NJ, UNITED STATES, August 5, 2025 /... |
| 23.10.2024 | Admera Health Expands its Reach with Strategic Acquisition of German-based BioEcho | The EchoLUTION Kit by BioEcho – a cutting-edge DNA/RNA extraction solution, now part of Admera Health’s expanded genomics toolkit, enabling faster and purer sample processing. Admera Health acquires Germany's BioEcho, boosting its NGS servi... |
| 12.06.2024 | Singleron Biotechnologies Appoints Admera Health as their Certified US Service Provider | Welcome to the Advanced Molecular Era BOSTON, MASSACHUSETTS, UNITED STATES, June 12, 2024 /EINPresswire.com/ -- Singleron Biotechnologies and Admera Health announced their strategic alliance at this year’s Festival of Genomics & Biodata... |
| 04.04.2024 | STOmics to Welcome Admera Health into its Certified Service Provider Program | STOmics to Welcome Admera Health into its Certified Service Provider program for Stereo-seq, its Spatial Transcriptomics platform. SAN DIEGO, CALIFORNIA, USA, April 4, 2024 /EINPresswire.com/ -- Admera Health, a leading provider of Next-Gen... |
| 29.03.2023 | Admera Health Announces its Acquisition of a NovaSeq X Plus | Welcome to the Advanced Molecular Era The NovaSeq X Plus is a game-changer in the world of sequencing, and we are excited to leverage its capabilities to advance sequencing-based research” — Yun Zhao, CEO SOUTH PLAINFIELD, NEW JERSEY, USA, ... |
| 17.08.2020 | Health tech companies claim their largest share of the Inc. 5,000 to date with 123 entries | |
| 23.08.2019 | 61 health tech companies report 2018 revenues, feature on Inc. 5,000 list | |
| 28.02.2017 | Mayo Clinic startup OneOme pitches user-friendly pharmacogenomics | The OneOme pharmacogenomic test kit Investigational drugs in the U.S. are required to undergo ‘ADME‘ pharmacology testing to characterize Absorption, Distribution, Metabolism and Excretion. The problem is that individuals process drugs diff... |
Show more